LILRB4 and leukemia: In addition to dramatically inhibit the self-renewal of leukemia stem cells, CS1 and CS2 have been reported to reprogram the immune response by suppressing the expression of the recently characterized immune checkpoint LILRB4, sensitize leukemia cells to cytotoxic T cells, and abate immune escape in mice.